Please login to the form below

Not currently logged in
Email:
Password:

Karus names two division heads

Simon Roitt and Peter Finan strengthen research team

karus-Simon-RoittUK-based biopharma Karus Therapeutics has appointed new heads for two of its research divisions.

Dr Simon Roitt joins as head of clinical development and Dr Peter Finan joins as head of biology.

Dr Roitt (pictured right) is formerly director of clinical operations at Roche in the UK, a position he held for nine years. Prior to this he was director of clinical research at GE Healthcare in the UK.

His new colleague Dr Finan joins Karus from Novartis where he spent 16 years. Most recently he was VP, global head – respiratory disease.

In his new role Dr Finan will work on Karus' most advanced programme, a treatment for inflammatory disorders.

Dr Simon Kerry, chief executive of Karus said: “As we develop the business, the recruitment of highly experienced senior talent to our team will be a critical success factor. Simon and Peter both bring valuable clinical and scientific expertise to the Company, to help drive our programmes towards the clinic.”

29th October 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics